share_log

康方生物：截至二零二三年十二月三十一日止月份股份發行人的證券變動月報表

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023

香港交易所 ·  Jan 5 04:21
Summary by Moomoo AI
康方生物科技（開曼）有限公司於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在該月份內無變動，維持在5,000,000,000股普通股，每股面值0.00001美元，法定/註冊股本總額為50,000美元。此外，公司於2022年6月28日採納的首次公開發售後購股權計劃下，本月底結存的股份期權數目為450,000，本月內無新增股份期權，也無股份期權被行使或註銷。報告中未提及有關香港預託證券的資料，並確認所有證券發行均已獲得董事會授權並符合相關法律規定。
康方生物科技（開曼）有限公司於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在該月份內無變動，維持在5,000,000,000股普通股，每股面值0.00001美元，法定/註冊股本總額為50,000美元。此外，公司於2022年6月28日採納的首次公開發售後購股權計劃下，本月底結存的股份期權數目為450,000，本月內無新增股份期權，也無股份期權被行使或註銷。報告中未提及有關香港預託證券的資料，並確認所有證券發行均已獲得董事會授權並符合相關法律規定。
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 January 2024 with Hong Kong Trading and Settlement Limited its Statement of Monthly Changes in Securities for the year ended 31 December 2023. THE REPORT SHOWS THAT THE COMPANY'S REGULATED/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE MONTH AT 5,000,000,000 SHARES OF ORDINARY SHARES WITH A FACE VALUE OF $0.00001 PER SHARE AND A TOTAL STATUTORY/REGISTERED SHARE CAPITAL OF $50,000. In addition, under the Company's Initial Public Offering Possession Option Plan adopted on June 28, 2022, the number of share options outstanding at the end of the month was 450,000, and no stock options were exercised or withdrawn during the month. The report does not mention information on Hong Kong pre-trust securities and confirms that all securities issuances have been authorised by the Board of Directors and comply with the relevant legal requirements.
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 January 2024 with Hong Kong Trading and Settlement Limited its Statement of Monthly Changes in Securities for the year ended 31 December 2023. THE REPORT SHOWS THAT THE COMPANY'S REGULATED/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE MONTH AT 5,000,000,000 SHARES OF ORDINARY SHARES WITH A FACE VALUE OF $0.00001 PER SHARE AND A TOTAL STATUTORY/REGISTERED SHARE CAPITAL OF $50,000. In addition, under the Company's Initial Public Offering Possession Option Plan adopted on June 28, 2022, the number of share options outstanding at the end of the month was 450,000, and no stock options were exercised or withdrawn during the month. The report does not mention information on Hong Kong pre-trust securities and confirms that all securities issuances have been authorised by the Board of Directors and comply with the relevant legal requirements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more